Insider Buying: Braveheart Bio (NASDAQ:BRVE) Major Shareholder Acquires $34,560,000.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) major shareholder Growth Opportunities Forbion purchased 1,920,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $34,560,000.00. Following the purchase, the insider owned 11,640,546 shares in the company, valued at $209,529,828. This represents a 19.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Braveheart Bio Trading Up 0.7%

Shares of Braveheart Bio stock traded up $0.20 during mid-day trading on Friday, reaching $30.00. 566,582 shares of the stock were exchanged. Braveheart Bio, Inc. has a fifty-two week low of $28.47 and a fifty-two week high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.